vs
艾伯维（ARGX）与HALOZYME THERAPEUTICS, INC.（HALO）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是HALOZYME THERAPEUTICS, INC.的5.5倍（$2.5B vs $451.8M）。艾伯维净利率更高（35.5% vs -31.3%，领先66.8%）。艾伯维同比增速更快（83.2% vs 51.6%）。艾伯维自由现金流更多（$322.4M vs $217.6M）
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
ARGX vs HALO — 直观对比
营收规模更大
ARGX
是对方的5.5倍
$451.8M
营收增速更快
ARGX
高出31.6%
51.6%
净利率更高
ARGX
高出66.8%
-31.3%
自由现金流更多
ARGX
多$104.8M
$217.6M
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $451.8M |
| 净利润 | $877.2M | $-141.6M |
| 毛利率 | 89.5% | 82.6% |
| 营业利润率 | 28.9% | -20.6% |
| 净利率 | 35.5% | -31.3% |
| 营收同比 | 83.2% | 51.6% |
| 净利润同比 | 1.3% | -203.3% |
| 每股收益（稀释后） | $13.25 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARGXHALO
| Q4 25 | $2.5B | $451.8M | ||
| Q3 25 | — | $354.3M | ||
| Q2 25 | $1.8B | $325.7M | ||
| Q1 25 | — | $264.9M | ||
| Q4 24 | $1.4B | $298.0M | ||
| Q3 24 | — | $290.1M | ||
| Q2 24 | $901.9M | $231.4M | ||
| Q1 24 | — | $195.9M |
净利润ARGXHALO
| Q4 25 | $877.2M | $-141.6M | ||
| Q3 25 | — | $175.2M | ||
| Q2 25 | $414.8M | $165.2M | ||
| Q1 25 | — | $118.1M | ||
| Q4 24 | $865.6M | $137.0M | ||
| Q3 24 | — | $137.0M | ||
| Q2 24 | $-32.5M | $93.2M | ||
| Q1 24 | — | $76.8M |
毛利率ARGXHALO
| Q4 25 | 89.5% | 82.6% | ||
| Q3 25 | — | 84.4% | ||
| Q2 25 | 89.2% | 85.8% | ||
| Q1 25 | — | 81.7% | ||
| Q4 24 | 90.2% | 85.9% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | 89.4% | 82.9% | ||
| Q1 24 | — | 85.5% |
营业利润率ARGXHALO
| Q4 25 | 28.9% | -20.6% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | 19.2% | 62.2% | ||
| Q1 25 | — | 53.4% | ||
| Q4 24 | 8.7% | 58.9% | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | -15.4% | 50.7% | ||
| Q1 24 | — | 48.8% |
净利率ARGXHALO
| Q4 25 | 35.5% | -31.3% | ||
| Q3 25 | — | 49.5% | ||
| Q2 25 | 23.4% | 50.7% | ||
| Q1 25 | — | 44.6% | ||
| Q4 24 | 64.1% | 46.0% | ||
| Q3 24 | — | 47.2% | ||
| Q2 24 | -3.6% | 40.3% | ||
| Q1 24 | — | 39.2% |
每股收益（稀释后）ARGXHALO
| Q4 25 | $13.25 | $-1.13 | ||
| Q3 25 | — | $1.43 | ||
| Q2 25 | $6.32 | $1.33 | ||
| Q1 25 | — | $0.93 | ||
| Q4 24 | $13.33 | $1.06 | ||
| Q3 24 | — | $1.05 | ||
| Q2 24 | $-0.55 | $0.72 | ||
| Q1 24 | — | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5B | $133.8M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | $7.3B | $48.8M |
| 总资产 | $8.7B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 43.89× |
8季度趋势，按日历期对齐
现金及短期投资ARGXHALO
| Q4 25 | $3.5B | $133.8M | ||
| Q3 25 | — | $419.7M | ||
| Q2 25 | $2.1B | $61.9M | ||
| Q1 25 | — | $176.3M | ||
| Q4 24 | $1.5B | $115.8M | ||
| Q3 24 | — | $154.3M | ||
| Q2 24 | $1.4B | $187.9M | ||
| Q1 24 | — | $164.6M |
总债务ARGXHALO
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $11.0M | $1.5B | ||
| Q1 24 | — | $1.5B |
股东权益ARGXHALO
| Q4 25 | $7.3B | $48.8M | ||
| Q3 25 | — | $503.9M | ||
| Q2 25 | $6.1B | $332.7M | ||
| Q1 25 | — | $482.3M | ||
| Q4 24 | $5.5B | $363.8M | ||
| Q3 24 | — | $452.7M | ||
| Q2 24 | $4.3B | $289.4M | ||
| Q1 24 | — | $177.8M |
总资产ARGXHALO
| Q4 25 | $8.7B | $2.5B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | $7.2B | $2.1B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | $6.2B | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | $4.8B | $2.0B | ||
| Q1 24 | — | $1.8B |
负债/权益比ARGXHALO
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | 0.00× | 5.19× | ||
| Q1 24 | — | 8.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $323.3M | $219.0M |
| 自由现金流经营现金流 - 资本支出 | $322.4M | $217.6M |
| 自由现金流率自由现金流/营收 | 13.0% | 48.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | 0.37× | — |
| 过去12个月自由现金流最近4个季度 | $594.5M | $644.6M |
8季度趋势，按日历期对齐
经营现金流ARGXHALO
| Q4 25 | $323.3M | $219.0M | ||
| Q3 25 | — | $178.6M | ||
| Q2 25 | $361.8M | $99.7M | ||
| Q1 25 | — | $154.2M | ||
| Q4 24 | $41.9M | $178.5M | ||
| Q3 24 | — | $115.4M | ||
| Q2 24 | $-124.7M | $55.8M | ||
| Q1 24 | — | $129.4M |
自由现金流ARGXHALO
| Q4 25 | $322.4M | $217.6M | ||
| Q3 25 | — | $175.6M | ||
| Q2 25 | $356.6M | $98.1M | ||
| Q1 25 | — | $153.3M | ||
| Q4 24 | $40.9M | $175.4M | ||
| Q3 24 | — | $113.9M | ||
| Q2 24 | $-125.5M | $53.2M | ||
| Q1 24 | — | $125.9M |
自由现金流率ARGXHALO
| Q4 25 | 13.0% | 48.2% | ||
| Q3 25 | — | 49.6% | ||
| Q2 25 | 20.1% | 30.1% | ||
| Q1 25 | — | 57.9% | ||
| Q4 24 | 3.0% | 58.9% | ||
| Q3 24 | — | 39.3% | ||
| Q2 24 | -13.9% | 23.0% | ||
| Q1 24 | — | 64.3% |
资本支出强度ARGXHALO
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | 0.3% | 0.5% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | 0.1% | 1.0% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | 0.1% | 1.1% | ||
| Q1 24 | — | 1.8% |
现金转化率ARGXHALO
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | 0.87× | 0.60× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | 0.05× | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 1.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARGX
暂无分部数据
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
